Indivi partners with Biogen to advance digital biomarkers for Parkinson's

Indivi, a prominent MedTech company based in Basel, Switzerland, has partnered with Biogen to advance digital health technology and create digital biomarkers for Parkinson's disease. The agreement includes licensing Indivi's smartphone-based digital biomarker platform, KonectomTM, to Biogen. KonectomTM enables remote assessment of neurological functions, offering more precise and frequent measurements of disease progression.

As part of the collaboration, Indivi will oversee the digital management of KonectomTM in Biogen's Phase 2b LUMA study, evaluating the efficacy and safety of BIIB122 for early-stage Parkinson’s disease. Indivi will ensure the continuous deployment of KonectomTM and collaborate with Biogen to develop and validate novel digital endpoints for Parkinson’s disease, as well as explore other disease areas for endpoint development.

Indivi's CEO, Guilhem Dupont, sees this collaboration as an opportunity to expand their technology into Parkinson's disease research, building on their success in multiple sclerosis. Indivi's advanced computational and statistical modelling methods aim to provide more precise measures of Parkinson’s disease progression, addressing the limitations of current clinical measurement instruments.

Indivi specialises in developing digital biomarkers for neuroscience, aiming to revolutionise drug development and healthcare. By combining KonectomTM with their existing digital biomarker platform for multiple sclerosis, dreaMSMD, Indivi aims to offer a comprehensive digital measurement technology solution for neurological research and development.

Click here to read the original news story.